Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | March 09, 2026 | March 12, 2026 |
| Vaxart, Inc.AVIR · Entity 6654 | Director · CEO | April 03, 2017 | April 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 09, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09 | Direct | 25,640 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 25,640 · Balance 25,640 F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Vaxart, Inc.
Report date April 03, 2017 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2027-04-03 | Direct | 2,113,304 |
Reported balance
After 2017-04-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-03 · Grant · Acquired 650,000 · Balance 2,113,304 F1: This stock option vests as follows: 33% of the total stock option vests six (6) months after the grant date, on October 3, 2017 and the remainder of the stock option vests in equal monthly installments beginning November 3, 2017 to April 3, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests as follows: 33% of the total stock option vests six (6) months after the grant date, on October 3, 2017 and the remainder of the stock option vests in equal monthly installments beginning November 3, 2017 to April 3, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 12, 2026 01:17 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 25,640 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026586 · tm268588-4_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,640 Underlying: Common Stock · 25,640 shares Expires 2036-03-09 F1 · derivative.exercise_date: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:20 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010564 · tm255864-6_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,343 Underlying: Common Stock · 54,343 shares Expires 2035-02-05 F1 · derivative.exercise_date: The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:05 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035732 · tm249071-4_4seq1.xml · derivative · entry 2 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,009 Underlying: Common Stock · 54,343 shares Expires 2034-03-14 F2 · derivative.exercise_date: The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:05 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 39,666 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035732 · tm249071-4_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,666 Underlying: Common Stock · 39,666 shares Expires 2034-03-14 F1 · derivative.exercise_date: The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:54 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 10,461 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001104659-23-129368 · tm2333426-2_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 Underlying: Common Stock · 10,461 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock option vests immediately prior to the Company's 2024 annual shareholders meeting. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 19:50 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001104659-22-046446 · tm2212851-4_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:26 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001104659-21-078787 · tm2119245-3_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 21:11 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-20-133643 · tm2038059-10_4seq1.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| May 22, 2019 Filed May 25, 2019 01:30 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 27,383 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001144204-19-028257 · tv522363_4.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 Underlying: Common Stock · 27,383 shares Expires 2029-05-22 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 17:09 UTC | Vaxart, Inc. AVIR · Entity 6654 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.66 Strike: $0.66 | $426,400.00 |
DisclosureSEC source: 0001437749-17-006117 · rdgdoc.xml · derivative · entry 1 PATTI JOSEPH M · CIK 0001283215 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,113,304 Underlying: Common Stock · 650,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: This stock option vests as follows: 33% of the total stock option vests six (6) months after the grant date, on October 3, 2017 and the remainder of the stock option vests in equal monthly installments beginning November 3, 2017 to April 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.